Pramod Ganta, MD
Hematology & Oncology · Anderson, SCNPI 1841236395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,709 of the $3,985 with a category attached, or 68.0%. 39 manufacturers reported payments, led by US Oncology Corporate, Inc. at 32.1% of the total. Reporting peaked in 2023 at $1,564 and has fallen 88.0% since, to $188 in 2025. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 119 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Oncology Corporate, Inc.$1K
- Incyte Corporation$599
- AstraZeneca$311
- Tersera Therapeutics LLC$192
- Amgen$181
- Novartis$166
- plus $1K from 33 others
Across 1 payment — averaging $270.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$270
What the payments were for
- Speaking & faculty fees$2005%
- Travel & lodging$62716%
- Food & beverage$2,70968%
- Education$42911%
- Gifts$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Oncology Corporate, Inc. | 6 | $1,279 |
| Incyte Corporation | 24 | $599 |
| AstraZeneca(2 entities) | 7 | $311 |
| Tersera Therapeutics LLC | 7 | $192 |
| Amgen | 11 | $181 |
| Novartis | 7 | $166 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $152 |
| ASD Specialty Healthcare, LLC | 3 | $117 |
| Octapharma USA, Inc. | 1 | $65 |
| Johnson & Johnson | 1 | $64 |
| AbbVie(2 entities) | 4 | $64 |
| Pfizer | 3 | $55 |
| ADMA Biomanufacturing LLC | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Eisai Inc. | 3 | $48 |
| Pharmacosmos Therapeutics Inc. | 2 | $46 |
| Rigel Pharmaceuticals, Inc. | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| G1 Therapeutics, Inc. | 2 | $41 |
| Sobi, Inc | 2 | $36 |
| Gilead(2 entities) | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Merck | 2 | $33 |
| GSK | 2 | $30 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Myovant Sciences Inc. | 1 | $25 |
| Partner Therapeutics, Inc. | 1 | $21 |
| CSL Behring | 1 | $21 |
| Eagle Pharmaceuticals, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $15 |
| Blue Earth Diagnostics | 1 | $13 |
| Dova Pharmaceuticals | 1 | $12 |
| Sanofi | 1 | $12 |
| Exelixis Inc. | 1 | $11 |
| Bayer | 1 | $11 |
How this compares
$3,985 in reported general payments places this provider in the 45th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 25 | $199,897 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $81,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,691 |
| OzempicSemaglutide | 11 | $17,634 |
| JanuviaSitagliptin Phosphate | 18 | $13,661 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 313 | $10,109 |
| Gabapentin | 84 | $1,715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,493 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,414 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $1,175 |
| Doxycycline Hyclate | 25 | $1,136 |
| Atorvastatin Calcium | 91 | $972 |
| Clonazepam | 91 | $890 |
| Oxycodone Hcl | 68 | $850 |
| Celecoxib | 29 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $55 | $199,89725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $49 | $81,31926 claims |
| GSKTrelegy Ellipta | $30 | $18,69126 claims |
| MerckJanuvia | $33 | $13,66118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Anderson
- James McClainAnderson$24K
- John DosterAnderson$17K
- Jeffrey DeloAnderson$15K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.